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httcense.Abstract Background: Lung cancer is the leading cause of cancer-relatedmortality in theUnited States.
Cigarette smoking is the number one risk factor for lung cancer. It causes about 90% of lung cancers (14).
Objective: Evaluation of bronchoalveolar lavage level of PGE2 in patients with primary bronchogenic
carcinoma.
Subjects and methods: The study was conducted on forty subjects; including twenty patients with bron-
chogenic carcinoma, ten patients with non-malignant lesions, and ten healthy control subjects. All subjects
were submitted to ﬁberoptic bronchoscopy with bronchoalveolar lavage was done and examined for pros-
taglandin E2.
Results: The PGE2 level was signiﬁcantly higher in BALF of group III (malignant group) compared to
group I & II, with no signiﬁcant difference between group I and group II. The cut- off value of PGE2 was
45.63 pg/ml with minimal overlap between malignant and benign lesions.
Conclusions: Bronchoalveolar lavage level ofPGE2was signiﬁcantly increased inpatientswithbroncho-
genic carcinoma.
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Lung cancer is the most common cause of cancer mortality in
both males and females. It constitutes 12.8% of cancer cases
and causes 17.8% of cancer death worldwide Overall, the glo-
bal incidence of lung cancer is increasing at rate of 0.5% per a
year [1,2].
Rising incidence of lung cancer has been shown to be
closely linked to increasing cigarette smoking [3,4]. The 5-year
relative survival rate from 1995 to 2001 for patients with lung
cancer was 15.7%. The 5-year relative survival rate variesis. Production and hosting by Elsevier B.V.
.10.028
168 G. Elkhouly et al.markedly depending on the stage at diagnosis, from 49% to
16% to 2% for patients with local, regional, and distant stage
disease, respectively [5].
A tumour marker is a substance produced by a tumour it-
self or produced by the host in response to a tumour, that can
be used to differentiate a malignant disease from a benign one.
Tumour markers can be determined easily in body ﬂuids like
blood and/or bronchoalveolar lavage (BAL) ﬂuid, therefore
many physicians consider them as useful diagnostic and prog-
nostic tools [6].
Prostaglandins are found in most tissues and organs. They
are produced by almost all nucleated cells. Prostaglandins are
not endocrine hormones, but autocrine or paracrine, which are
locally acting messenger molecules. They differ from hormones
in that they are not produced at a discrete site but in many
places throughout the human body. Also, their target cells
are present in the immediate vicinity of the site of their secre-
tion [7,8].
Prostaglandins ligate a sub-family of cell surface
seven-transmembrane receptors, G-protein-coupled receptors.
These receptors are termed DP1-2, EP1-4, FP, IP1-2,
and TP, corresponding to the receptor that ligates the corre-
sponding prostaglandin (e.g., DP1-2 receptors bind to
PGD2) [9].
Prostaglandins are potent but have a short half-life before
being inactivated and excreted. Increased amounts of PGE2
are produced in several pathologic conditions, including
inﬂammation, arthritis, fever, tissue injury, endometriosis
and a wide variety of cancers [10–12].
Prostaglandin E2 (PGE2) mediates several hallmarks of
cancer: During early neoplastic transformation, PGE2 acti-
vates the epidermal growth factor receptor (EGFR) to enhance
cell proliferation [13] and up-regulates surviving concentra-
tions in tumors to decrease apoptosis [14]. At later stages of
progression, PGE2 up-regulates the biosynthesis of vascular
endothelial growth factor (VEGF) expression, which stimu-
lates angiogenesis [15], increases IL-10 biosynthesis to inhibit
adaptive antitumor immune responses [16] and augments pro-
tease expression, thereby promoting invasion [17].
Objective of the study
The aim of this work is to evaluate PGE2 level in bronchoal-
veolar lavage ﬂuid to clarify its role as a diagnostic marker
in patients with bronchogenic carcinoma.Subjects and methods
This study was carried out on 40 subjects selected from inpa-
tients and outpatients of Chest Department Tanta University
Hospital from May 2011 to February 2012.Table 1 Mean values (±SD) and Statistical comparison of
BALF level of PGE2 in groups I, II and III.
PGE2 level ANOVA
Range Mean ± SD F P value
GI 25–40 32.6 ± 8.11 14.620 0.001
GII 40–60 47.53 ± 8.60
GIII 150–280 199.9 ± 22.8The subjects were classiﬁed into three groups
Group I: Included ten healthy non smokers volunteers (con-
trol group).
Group II: Included ten patients with benign pulmonary dis-
eases; 2 patients with COPD, 2 asthmatic patients, 3 patients
with pneumonia, 2 patients with lung abscess and one patient
with old T.B. Their ages ranged between 45 and 58 years with a
mean 51.69 ± 5.30 years.Group III: Included twenty patients with bronchogenic car-
cinoma (conﬁrmed by histopathological examination of BAL,
brush and/or biopsy). Their ages ranged between 45 and
65 years with a mean of 54.47 ± 8.30 years.
After an informed written consent was taken from all subjects
Full history taking, complete clinical examination, plain chest
X-ray posteroanterior and lateral view, CT Scan of the chest
for some patients of benign pulmonary diseases in group II
and all patients in group III were done. Bronchoalveolar la-
vage was done to all patients under local anaesthesia using
ﬂexible ﬁberoptic bronchoscopy (Olympus BF type P10) and
examined for PGE2 levels by enzyme linked immunosorbent
assay (ELISA).
Principle of the immunosorbent assay (ELISA)
This assay is based on the forward sequential competitive
binding technique in which PGE2 present in a sample com-
petes with horse radish peroxidase (HRP)-labeled PGE2 for
a limited number of binding sites on a mouse monoclonal anti-
body. PGE2 in the sample is allowed to bind to the antibody in
the ﬁrst incubation. During the second incubation, HRP-la-
beled PGE2 binds to the remaining antibody sites and fol-
lowed by a wash to remove unbound materials.
A substrate solution is added to the wells to determine the
bound enzyme activity. The color development is stopped and
the absorbance is read at 450 nm. The intensity of the color is
inversely proportional to the concentration of PGE2 in the
sample.
Statistical analysis
Statistical presentation and analysis of the present study was
conducted, using the mean, standard deviation, unpaired stu-
dent t-test, analysis of variance [ANOVA] test, by SPSS V18.
The sensitivity, speciﬁcity and accuracy were calculated by
using receiver operating characteristic (ROC) analysis.
Results
A forty subjects were included in our study, divided into three
groups; Ten healthy subjects as control group (group I), ten
patients with non-malignant lung diseases (group II), and
twenty patients with bronchogenic carcinoma (group III).
The mean values of age in group I, group II, and group III
were 47.63 ± 4.63, 51.69 ± 5.30, and 54.47 ± 8.30, respec-
tively. There was no signiﬁcant difference in age in the three
studied groups (P= 0.632).
Table 2 Mean values (±SD) and Statistical comparison of
BALF level of PGE2 in subgroups IIIA, IIIB, and IIIC.
PGE2 level ANOVA
Range Mean ± SD F P value
IIIA 200-280 221.60 ± 18.63 6.325 0.004
IIIB 150-200 187.22 ± 9.62
IIIC 120-150 133.80 ± 7.10
Figure 1 ROC curve for PGE2 level in BALF in group III. The
plot was constructed by computing the sensitivity vs. speciﬁcity for
the different possible cutoff points.
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and III were 32.6 ± 8.11, 47.53 ± 8.60, and 199.9 ± 22.8,
respectively. PGE2 was signiﬁcantly higher in group III
compared to groups I & II (F= 14.62, P= 0.001). While
there was no signiﬁcant difference between group I and group
II (P= 0.01), (Table 1).
The patients of group III were divided according to histo-
pathological ﬁndings into three subgroubs: IIIA; 8 patients
diagnosed as squamous cell carcinoma (40%), with 7 males
and one female, IIIB: 7 patients diagnosed as adenocarcinoma
(35%), with 6 males and one female, and IIIC: 5 patients diag-
nosed as large cell carcinoma (25%), all of them were males.
The mean values of PGE2 (pg/ml) in BALF in groups IIIA,
IIIB and IIIC were 221.60 ± 18.63, 187.22 ± 9.62 and
133.80 ± 7.10 respectively. PGE2 level was signiﬁcantly higher
in subgroup IIIA compared to subgroups IIIB & IIIC
(F= 6.32, P= 0.004). There was no marked difference in
PGE2 levels in subgroups IIIB &IIIC (P= 0.009) (see Table
2).
The cut-off value of bronchoalveolar lavage ﬂuid PE2 for
diagnosis of malignant lung diseases was 45.63 with sensitivity
(80%), speciﬁcity (85%), +ve predictive value (88%), and – vepredictive value (16%). Analysis of the ROC curve for the PE2
in the BALF is shown in Fig. 1.Discussion
In the present study, the PGE2 level in BALF was signiﬁcantly
higher in groupe III compared to group I&II, with no signiﬁ-
cant difference between group I and group II.
These results are in agreement with the results obtained by
Bennett et a1. [18], who compared PGE2 from tumor tissues
and ‘‘normal tissues’’ from the same lung and found that car-
cinomatous tissues contained a signiﬁcantly larger amount of
PGE2 than ‘‘normal lung tissue’’ .These observations sug-
gested that tumor cells or cells associated with tumor in the tis-
sue such as monocytes/macrophages, are the origin of the
increased PGE2 observed in the tumor tissue.
Also, LeFever and Funahashi [19],who had measured the
concentration of PGE2 in BALF of patients with lung carci-
noma and found it to be elevated in 18 patients with primary
lung cancer as compared with 6 patients with lung diseases
other than lung cancer and 10 normal subjects.
In the present study, PGE2 level was signiﬁcantly higher in
subgroup IIIA compared to subgroups IIIB& IIIC, with no
marked difference in PGE2 levels in subgroups IIIB and IIIC.
These results are in agreement with the results obtained by
Funahashi et al. [20], who found that any malignant process,
either primary lung cancer or metastatic cancer from other or-
gans, is associated with an increased PGE2 content in BALF.
Also, he found that BALF PGE2 content is signiﬁcantly higher
in patients with SQCA as compared with patients with ADCA
or SCCA. Moreover, he found a decrease of BALF PGE2 lev-
els observed after successful removal of cancer to the range
seen in patients with pulmonary diseases other than cancer.
On the other hand, Hida et al. [21], reported that increased
expression of cyclooxygenase 2 occurs frequently in human lung
cancers, speciﬁcally in adenocarcinomas. Also, Yoshimatsu
et al. [22], who investigated the expression of PGES, a glutathi-
one-dependent, membrane-bound enzyme that converts PGH2
into PGE2. He demonstrated that PGES levels were increased
in NSCLCs relative to normal tissue and mutant ras, which is
found in 30–50% of lung adenocarcinomas.
In the present study the cut- off value of PGE2 was 45.63
(pg/ml) with minimal overlape between cancer and benign le-
sions. Funahashi et al. [20], reported that the ability of
PGE2 to differentiate malignant fom benign lesion shown by
the difference in the mean values of PGE2 between lung cancer
and noncarcinomatous benign lesions, with a BALF PGE2 va-
lue of 51 pg/ml was used as a cut-off value between cancer and
benign lesions.Conclusion
The PGE2 level in BALF was signiﬁcantly higher in malignant
group, with the ability to differentiate malignant from benign
lesions. Further studies should be carried out on a large
population to study the correlation of PGE2 level with the
lung cancer stage and to asses the value of this marker in mon-
itoring the patients after therapy concerning the tumour re-
sponse and its importance in early detection of tumour
recurrence.
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